Venture capitalists like nothing more than pattern matching, and Domain Associates has identified one it especially prefers: licensing drug candidates from a Japanese biopharma and setting up a US company to move it through testing until Big Pharma starts nosing around.
It’s a roadmap the VC firm, which has offices in San Diego and Princeton, NJ, is looking to again follow with its latest investment: a $15 million Series A financing round that Domain and fledgling firm Catalys Pacific pulled together to launch Exalys Therapeutics.
The new San Diego-based biotech plans to move ahead three potential drug candidates licensed from Japan’s… Read more »
UNDERWRITERS AND PARTNERS
